Fig. 2: Cdx2 expression in HSPC results in lethal and transplantable disease.

a Representative Wright-Giemsa stained PB smears showing distinct phenotypes of Scl-Cre (normal) and Scl:Cdx2 mice at disease onset. Scale bars on bottom right of each image indicate 10 µm. MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; AL, acute leukemia. b Incidence of hematological disease in Scl-Cre (n = 18) and Scl:Cdx2 (n = 22) mice after 60 weeks of monitoring. (c) White blood cell (WBC) counts of Scl:Cdx2 mice (n = 18) at date of sacrifice and assignment of disease diagnosis. The identification numbers of mice with acute leukemia are indicated. d Leukocyte counts (WBC), (e) hemoglobin, f platelet counts, and g spleen size relative to body mass of mice at sacrifice. (WT n = 6; Scl-cre n = 8; Scl:Cdx = 18 [MDS n = 7; MPN/AL n = 11]). h Table showing acute leukemia immunophenotype in mCherry⁺cKit⁺ PB cells of Scl:Cdx2 mice at disease onset and transplantability status of these cells. i Representative flow cytometry of PB from mice transplanted with Scl:Cdx2 #2259 acute leukemia BM cells. j Survival curve of secondary leukemia mice transplanted with varying cell numbers of Scl:Cdx2 #882 BM cells (n = 10). N = biologically independent animals. Statistical analyses performed using two-tailed Mann–Whitney test. Log-rank Mantel-Cox test used for survival curve. Data are plotted as mean values +/− SD. n.s.; not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.